ArriVent reports FY2025 net loss of $166.3M; cash of $312.8M funds into 3Q 2027

ArriVent BioPharma, Inc.

Cash and investments of $312.8M as of Dec 31, 2025; expected to fund operations into 3Q 2027.
Net loss $166.3M in FY2025 vs $80.5M in FY2024; R&D expenses $153.4M (incl. one-time payment to Lepu).
Topline pivotal Phase 3 data for firmonertinib in first-line EGFR exon20ins NSCLC expected mid-2026.
Phase 3 ALPACCA study for firmonertinib in EGFR PACC mutant NSCLC dosed first patient in Dec 2025.
ADC lead ARR-217 in Phase 1 dose escalation; IND clearance received; first patient dosed March 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ArriVent BioPharma, Inc. reported the year ended December 31, 2025 results: net income Net loss was $166.3 million.

Period: the year ended December 31, 2025
Net income: Net loss was $166.3 million
Result: reported results

Exact text from the filing

ArriVent BioPharma, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025.

View on SEC.gov

Browse all earnings releases →

ArriVent BioPharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-024112

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.